🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

74 results for “C4” Clear

  1. 35 mg oral lyophilisate, 25 mg oral lyophilisate, 50 mg oral lyophilisate, VYDURA 75 mg oral lyophilisate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Acute Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  2. Afinitor 10 mg tablets, Aromasin 25 mg coated tablets, Faslodex 250 mg solution for injection., Afinitor 5 mg tablets

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Hormone receptor-positive, her2-negative advanced/metastatic breast cancer

    phase 3 small molecule active

    1 trial

  3. CAPECITABINE, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Oxaliplatin 5mg/ml concentrate for solution for infusion, CETUXIMAB, ENCORAFENIB, Calcium Folinate 10 mg/ml Injection, CAMPTO 20 mg/mL concentrate for solution for infusion, Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion, CAMPTO 20 mg/mL concentrate for solution for infusion, FLUOROURACIL, IRINOTECAN, Bevacizumab, CALCIUM FOLINATE, Capecitabine, Cetuximab, OXALIPLATIN, Oxaliplatin 5mg/ml concentrate for Solution

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Colorectal cancer (BRAF V600E-mutant mCRC)

    phase 3 small molecule active

    1 trial

  4. ENCORAFENIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Binimetinib placebo, BINIMETINIB, Encorafenib Pacebo

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 3 small molecule active

    1 trial

  5. EVEROLIMUS, EVEROLIMUS, PF-07248144, FULVESTRANT, EVEROLIMUS, EXEMESTANE, FULVESTRANT, PF-07248144

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  6. GC4419 90mg

    Galera Therapeutics

    Oral Mucositis

    phase 3 small molecule completed

    1 trial

  7. LETROZOLE, IBRANCE 75 mg hard capsules, RIBOCICLIB, ABEMACICLIB, IBRANCE 100 mg hard capsules, ABEMACICLIB, IBRANCE 125 mg hard capsules, ABEMACICLIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Advanced/Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  8. NIRMATRELVIR, NIRMATRELVIR, Ritonavir, nirmatrelvir / ritonavir

    Pfizer Ireland Pharmaceuticals Unlimited Company

    SARS-CoV-2 Infection

    phase 3 small molecule active

    1 trial

  9. RIMEGEPANT SULFATE, Placebo to rimegepant sulfate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  10. RO7795068, RO7795068, RO7795068 Placebo, RO7795068, RO7795068, RO7795068, RO7795068

    Roche Registration Limited

    Obesity or Overweight and Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  11. RO7795068, RO7795068, RO7795068, RO7795068, RO7795068, RO7795068 Placebo, RO7795068

    Roche Registration Limited

    Obesity or Overweight Without Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  12. Rimegepant Placebo, VYDURA 75 mg oral lyophilisate, 35 mg oral lyophilisate, 25 mg oral lyophilisate, 50 mg oral lyophilisate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  13. VYDURA 75 mg oral lyophilisate, 35 mg oral lyophilisate, Placebo for 75 mg Rimegepant, Placebo for 50 mg rimegepant, 50 mg oral lyophilisate, Placebo for 35 mg rimegepant, Placebo for 25 mg Rimegepant, 25 mg oral lyophilisate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Acute Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  14. VYDURA 75 mg oral lyophilisate, matching placebo for 75 mg oral lyophilisate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Menstrual Migraine

    phase 3 small molecule active

    1 trial

  15. BINIMETINIB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB, IPILIMUMAB, ENCORAFENIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 2 small molecule active

    1 trial

  16. C4531002-A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult Participants with Moderate-Severe Atopic Dermatitis.

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Moderate-Severe Atopic Dermatitis

    phase 2 other active

    1 trial

  17. C4531029:A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-07275315 in Adult Participants with Inadequately Controlled Moderate-to-Severe Asthma

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Moderate-to-severe Asthma

    phase 2 other active

    1 trial

  18. CT7001, PF-07850327 round

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  19. Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Maplirpacept

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Relapsed/Refractory Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  20. Disitamab Vedotin (RC48)

    First Tracks Biotherapeutics

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  21. Drug GC4711

    Galera Therapeutics

    SBRT

    phase 2 small molecule terminated

    1 trial

  22. Drug: GC4419

    Galera Therapeutics

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  23. Encorafenib, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. FULVESTRANT, LETROZOLE

    Pfizer Ireland Pharmaceuticals Unlimited Company

    HR-positive HER2-negative metastatic/advanced BC

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources